This Attenuvax market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing incidence of measles, government-led vaccination programs, partnerships with global health organizations, expanded research efforts, and reduced logistical challenges.
Growth during the market's forecast period can be attributed to factors such as the expanding pediatric population, rising incidences of pneumococcal infections, increased public health campaigns, and a heightened focus on preventive healthcare. Key trends during this period include new product innovations, collaborations with international vaccine manufacturers, increased funding for immunization programs, advancements in vaccine technology, and improvements in pediatric healthcare.
The growing incidence of measles is expected to drive the growth of the attenuvax market moving forward. Measles is a highly contagious viral disease that primarily affects children and can lead to severe complications. The increasing incidence of measles is linked to factors such as declining vaccination rates, vaccine hesitancy, global travel, the erosion of herd immunity, weak healthcare systems, and anti-vaccine movements. Attenuvax provides a highly effective vaccine, offering immunity against measles, reducing the risk of infection, lessening the severity of symptoms, and preventing complications, thus supporting both patient health and public health initiatives. For example, in November 2024, the World Health Organization (WHO) reported an estimated 107,500 measles-related deaths worldwide in 2023. Additionally, the Centers for Disease Control and Prevention (CDC) reported 16 measles outbreaks in 2024, with 70% of cases linked to these outbreaks, compared to 4 outbreaks in 2023. As such, the rising incidence of measles is anticipated to drive the growth of the attenuvax market.
The increasing occurrence of infectious diseases is also expected to boost the attenuvax market in the future. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. The growing prevalence of these diseases is driven by factors such as globalization, urbanization, antimicrobial resistance, and environmental changes. Attenuvax contributes by providing an effective measles vaccine, stimulating immunity, preventing disease transmission, and reducing symptom severity, which improves patient outcomes and supports global public health efforts. For instance, the CDC reported a 5.9% increase in tuberculosis (TB) cases in the US from 2021 to 2022, with 8,331 cases reported in 2022. Therefore, the rising incidence of infectious diseases will contribute to the growth of the attenuvax market.
The rise in healthcare spending is expected to further fuel the growth of the attenuvax market. Healthcare spending refers to the financial resources allocated to healthcare services and products by individuals, governments, private insurers, and other entities. The increase in healthcare spending is driven by an aging population, advancements in medical technology, a growing prevalence of chronic diseases, and a higher demand for healthcare services. This increased spending supports Attenuvax by funding immunization programs, vaccine research, and development initiatives, thus enhancing disease prevention efforts and reducing the global burden of measles. For example, in May 2024, the UK’s Office for National Statistics reported a 5.6% increase in healthcare spending between 2022 and 2023, with the total healthcare expenditure reaching approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending will contribute to the growth of the attenuvax market.
The key company operating in the attenuvax market is Merck & Co. Inc.
North America was the largest region in the attenuvax market in 2024. The regions covered in attenuvax report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the attenuvax market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Attenuvax is a live attenuated vaccine used to prevent measles infection. It is primarily used to immunize individuals, especially children, against the highly contagious measles virus. The vaccine works by prompting the immune system to generate immunity against the disease without causing the illness itself.
The primary clinical indications for attenuvax include measles, mumps, and rubella. Measles is a highly contagious viral infection that can result in serious health complications. The Attenuvax vaccine is a live attenuated vaccine developed to stimulate the immune system and provide long-term protection against the virus. The various distribution channels for Attenuvax include hospital pharmacies, drug stores, retail pharmacies, and vaccination centers. It is used by various end users, such as hospitals, clinics, ambulatory care facilities, and home care settings.
The attenuvax market research report is one of a series of new reports that provides attenuvax market statistics, including attenuvax industry global market size, regional shares, competitors with a attenuvax market share, detailed attenuvax market segments, market trends and opportunities, and any further data you may need to thrive in the attenuvax industry. This attenuvax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The attenuvax market consists of sales of attenuvax single dose vials and reconstituted vaccine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing incidence of measles, government-led vaccination programs, partnerships with global health organizations, expanded research efforts, and reduced logistical challenges.
Growth during the market's forecast period can be attributed to factors such as the expanding pediatric population, rising incidences of pneumococcal infections, increased public health campaigns, and a heightened focus on preventive healthcare. Key trends during this period include new product innovations, collaborations with international vaccine manufacturers, increased funding for immunization programs, advancements in vaccine technology, and improvements in pediatric healthcare.
The growing incidence of measles is expected to drive the growth of the attenuvax market moving forward. Measles is a highly contagious viral disease that primarily affects children and can lead to severe complications. The increasing incidence of measles is linked to factors such as declining vaccination rates, vaccine hesitancy, global travel, the erosion of herd immunity, weak healthcare systems, and anti-vaccine movements. Attenuvax provides a highly effective vaccine, offering immunity against measles, reducing the risk of infection, lessening the severity of symptoms, and preventing complications, thus supporting both patient health and public health initiatives. For example, in November 2024, the World Health Organization (WHO) reported an estimated 107,500 measles-related deaths worldwide in 2023. Additionally, the Centers for Disease Control and Prevention (CDC) reported 16 measles outbreaks in 2024, with 70% of cases linked to these outbreaks, compared to 4 outbreaks in 2023. As such, the rising incidence of measles is anticipated to drive the growth of the attenuvax market.
The increasing occurrence of infectious diseases is also expected to boost the attenuvax market in the future. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. The growing prevalence of these diseases is driven by factors such as globalization, urbanization, antimicrobial resistance, and environmental changes. Attenuvax contributes by providing an effective measles vaccine, stimulating immunity, preventing disease transmission, and reducing symptom severity, which improves patient outcomes and supports global public health efforts. For instance, the CDC reported a 5.9% increase in tuberculosis (TB) cases in the US from 2021 to 2022, with 8,331 cases reported in 2022. Therefore, the rising incidence of infectious diseases will contribute to the growth of the attenuvax market.
The rise in healthcare spending is expected to further fuel the growth of the attenuvax market. Healthcare spending refers to the financial resources allocated to healthcare services and products by individuals, governments, private insurers, and other entities. The increase in healthcare spending is driven by an aging population, advancements in medical technology, a growing prevalence of chronic diseases, and a higher demand for healthcare services. This increased spending supports Attenuvax by funding immunization programs, vaccine research, and development initiatives, thus enhancing disease prevention efforts and reducing the global burden of measles. For example, in May 2024, the UK’s Office for National Statistics reported a 5.6% increase in healthcare spending between 2022 and 2023, with the total healthcare expenditure reaching approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending will contribute to the growth of the attenuvax market.
The key company operating in the attenuvax market is Merck & Co. Inc.
North America was the largest region in the attenuvax market in 2024. The regions covered in attenuvax report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the attenuvax market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Attenuvax is a live attenuated vaccine used to prevent measles infection. It is primarily used to immunize individuals, especially children, against the highly contagious measles virus. The vaccine works by prompting the immune system to generate immunity against the disease without causing the illness itself.
The primary clinical indications for attenuvax include measles, mumps, and rubella. Measles is a highly contagious viral infection that can result in serious health complications. The Attenuvax vaccine is a live attenuated vaccine developed to stimulate the immune system and provide long-term protection against the virus. The various distribution channels for Attenuvax include hospital pharmacies, drug stores, retail pharmacies, and vaccination centers. It is used by various end users, such as hospitals, clinics, ambulatory care facilities, and home care settings.
The attenuvax market research report is one of a series of new reports that provides attenuvax market statistics, including attenuvax industry global market size, regional shares, competitors with a attenuvax market share, detailed attenuvax market segments, market trends and opportunities, and any further data you may need to thrive in the attenuvax industry. This attenuvax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The attenuvax market consists of sales of attenuvax single dose vials and reconstituted vaccine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Attenuvax Market Characteristics4. Attenuvax Market Trends and Strategies5. Attenuvax Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Attenuvax Pricing Analysis & Forecasts30. Global Attenuvax Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Attenuvax Market32. Recent Developments in the Attenuvax Market
3. Attenuvax Market Biologic Drug Characteristics
6. Global Attenuvax Growth Analysis and Strategic Analysis Framework
8. Attenuvax Market Segmentation
9. Global Attenuvax Epidemiology of Clinical Indications
10. Attenuvax Market Regional and Country Analysis
11. Asia-Pacific Attenuvax Market
12. China Attenuvax Market
13. India Attenuvax Market
14. Japan Attenuvax Market
15. Australia Attenuvax Market
16. South Korea Attenuvax Market
17. Western Europe Attenuvax Market
18. UK Attenuvax Market
19. Germany Attenuvax Market
20. France Attenuvax Market
21. Eastern Europe Attenuvax Market
22. North America Attenuvax Market
23. USA Attenuvax Market
24. Canada Attenuvax Market
25. South America Attenuvax Market
26. Middle East Attenuvax Market
27. Africa Attenuvax Market
28. Attenuvax Market Competitive Landscape and Company Profiles
29. Global Attenuvax Market Pipeline Analysis
33. Attenuvax Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Attenuvax Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on attenuvax market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for attenuvax? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The attenuvax market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: Measles; Mumps; Rubella2) by Distribution channel: Hospital Pharmacies; Drug stores; Retail Pharmacies; Vaccination Centre
3) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Merck & Co. Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
